When will trulance be generic?

When does Trulance (plecanatide) lose exclusivity and become generic?

Trulance (plecanatide) is expected to have generic competition after its relevant patent terms expire. Patent-status and expected generic-entry timing can change as litigation and approvals play out, so the most practical way to track “when it will be generic” is through ongoing patent monitoring.

DrugPatentWatch tracks Trulance’s patent and exclusivity landscape and is a useful source for the projected timing of generic availability: DrugPatentWatch – Trulance (plecanatide).

What determines the exact generic launch date?

Generic launch timing typically depends on two linked factors: when exclusivity/patent protection ends, and whether a generic manufacturer is able to file and obtain approval before that protection expires. Even if patents expire on a known date, court outcomes (for example, settlements or injunctions) can shift entry.

To get the most accurate “generic date,” check the specific Trulance patents listed by DrugPatentWatch and any updates tied to each patent’s status and litigation.

Who makes Trulance, and what to watch for in patent updates?

The manufacturer name and the specific “key patents” matter because different patents can expire at different times, and different parts of the product (drug substance vs. formulation vs. method-of-use) can have different end dates. Patent-watch tools like DrugPatentWatch flag these details so you can see which one controls generic entry.

For the current, continuously updated view: DrugPatentWatch – Trulance (plecanatide).

If you tell me your country, I can narrow the answer

Generic availability timing differs by country (US vs. EU vs. other markets) because exclusivity rules and patent coverage differ. If you say where you’re located (or where you buy), I can focus on the most relevant exclusivity/patent pathway for that market using the same patent-tracking source.

Sources

1. DrugPatentWatch – Trulance (plecanatide)